10 Years Treating Bifurcations: Have We Made Progress?

Bifurcations have been, are and will be challenging. However, we have to admit we have gained experience and have more tools than pioneer interventionists and many of the early experts who have made history. 

10 años tratando bifurcaciones

This study assessed the ten-year trends in coronary bifurcation percutaneous coronary intervention (PCI) looking at patient and lesion characteristics, devices used, strategy and stent optimization techniques. 

It included over 5,000 patients receiving bifurcation PCI between 2004 and 2015. Primary end point at 2 years was target vessel failure (combination of cardiac death, MI and any revascularization).

During the 10-year study period patient and lesion grew in complexity: multivessel, diabetes, chronic kidney failure and left main disease rates increased gradually (p<0.001 for all).

On the other hand, the risk of target vessel failure saw a steady drop, from 12.3% in 2004 to 6.9% in 2015 (to nearly half).


Read also: Device Evolution Also Impacts on Valve in Valve.


The two variables driving outcome improvement were mainly second-generation drug eluting stents (not surprisingly), and the significant dip of true bifurcations (Medina 1,1,1 y 0,1,1).

Conclusion

During the last decade of bifurcation PCI, patient and lesion characteristics, devices, techniques and ultimately population prognosis have significantly changed. Although over time patients and lesions have become more complex, outcomes have improved thanks to device development, technique optimization and more appropriate strategies. 

JAHA-121-021632

Original Title: Ten-Year Trends in Coronary Bifurcation Percutaneous Coronary Intervention: Prognostic Effects of Patient and Lesion Characteristics, Devices, and Techniques.

Reference: Joo Myung Lee et al. J Am Heart Assoc. 2021 Sep 21;10(18):e021632. doi: 10.1161/JAHA.121.021632.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

Rotational atherectomy and its technical secrets: use of floppy or ES guidewire

Rotational atherectomy (RA) remains a very useful tool in the management of severe coronary calcification. However, many of its technical aspects rely more on...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...